# CAPItello-281 (NCT04493853)

> Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04493853
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Hormone-Sensitive Prostate Cancer
- Interventions: Capivasertib; Placebo; Abiraterone Acetate
- Enrollment: 1012
- Primary outcome: Radiographic Progression-free Survival (rPFS)

## Commentary we found

- X threads: 71
- YouTube: 50
- Podcasts: 28
- X videos: 6

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=capitello-281-nct04493853

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04493853", "email": "<work email>"}; the inbox owner confirms by the emailed link.